Toll-like Receptor 4 Gene Polymorphisms and Susceptibility to Bladder Cancer Research First Online: 12 October 2012 Received: 11 August 2012 Accepted: 24 September 2012 DOI :
10.1007/s12253-012-9579-8
Cite this article as: Shen, Y., Liu, Y., Liu, S. et al. Pathol. Oncol. Res. (2013) 19: 275. doi:10.1007/s12253-012-9579-8
7
Citations
169
Downloads
Abstract Bladder cancer is one of the most common malignancies in the world. Toll-like receptor 4 (TLR4) plays important roles in regulating innate immunity and may affect the development of cancers. Polymorphisms in TLR4 gene have been shown to be associated with impaired immune responses. Here, we investigated the association of TLR4 polymorphisms with bladder cancer. Four TLR4 polymorphisms (-2242T/C, Asp299Gly, Thr399Il3, and +3725G/C) were genotyped in a total number of 436 bladder cancer patients and 522 healthy controls. Data were analyzed using the Chi-square test. Results showed that the prevalence of TLR4 +3725GC and CC genotypes were significantly increased in bladder cancer cases than in controls (odds ratio [OR] = 1.58, 95 % confidence interval [CI] = 1.19–2.10, p = 0.0015, and OR = 2.33, 95%CI = 1.52–3.58, p < 0.0001, respectively). Also, the frequency of TLR4 +3725C allele was significantly higher in bladder cancer patients (p < 0.0001). The -2242T/C, Asp299Gly and Thr399Il3 polymorphisms did not reveal any significant differences between cases and controls. Stratification analysis of the clinical features in the patients demonstrated that cases with invasive cancer were correlated with higher numbers of +3725GC and CC genotype (p = 0.0004 and p = 0.0231). In conclusion, these results indicate that TLR4 +3725G/C polymorphism may be a novel risk factor for bladder cancer in the Chinese population.
Keywords Toll-like receptor 4 Polymorphism Bladder cancer
References 1.
Parkin DM (2004) International variation. Oncogene 23:6329–6340
PubMed CrossRef Google Scholar 2.
Yee DS, Ishill NM, Lowrance WT et al (2011) Ethnic differences in bladder cancer survival. Urology 78:544–549
PubMed CrossRef Google Scholar 3.
Cohen SM, Shirai T, Steineck G (2000) Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl 34:105–115
CrossRef Google Scholar 4.
Chow JC, Young DW, Golenbock DT et al (1999) Toll-like receptor 4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 274:10689–10692
PubMed CrossRef Google Scholar 5.
Shi H, Kokoeva MV, Inouye K et al (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116:3015–3025
PubMed CrossRef Google Scholar 6.
Schreibelt G, Tel J, Sliepen KH et al (2010) Tolllike receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 59:1573–1582
PubMed CrossRef Google Scholar 7.
Liu H, Komai-Koma M, Xu D et al (2006) Toll-like receptor 2 signaling modulates the functions of CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A 103:7048–7053
PubMed CrossRef Google Scholar 8.
Sutmuller RP, den Brok MH, Kramer M et al (2006) Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 116:485–494
PubMed CrossRef Google Scholar 9.
Kabelitz D (2007) Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 19:39–45
PubMed CrossRef Google Scholar 10.
Huang B, Zhao J, Li H et al (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65:5009–5014
PubMed CrossRef Google Scholar 11.
Kelly MG, Alvero AB, Chen R et al (2006) TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66:3859–3868
PubMed CrossRef Google Scholar 12.
Arbour NC, Lorenz E, Schutte BC et al (2000) TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25:187–191
PubMed CrossRef Google Scholar 13.
de Oliveira JG, Silva AE (2012) Polymorphisms of the TLR2 and TLR4 genes are associated with risk of gastric cancer in a Brazilian population. World J Gastroenterol 18:1235–1242
PubMed CrossRef Google Scholar 14.
Akil I, Ozkinay F, Onay H (2012) Assessment of Toll-like receptor-4 gene polymorphism on pyelonephritis and renal scar. Int J Immunogenet 39:303–307
PubMed CrossRef Google Scholar 15.
Agúndez JA, García-Martín E, Devesa MJ (2012) Polymorphism of the TLR4 gene reduces the risk of hepatitis C virus-induced hepatocellular carcinoma. Oncology 82:35–40
PubMed CrossRef Google Scholar 16.
Creely SJ, McTernan PG, Kusminski CM, Fisher M (2007) Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292:E740–E747
PubMed CrossRef Google Scholar 17.
Manolakis AC, Kapsoritakis AN, Tiaka EK et al (2011) TLR4 gene polymorphisms: evidence for protection against type 2 diabetes but not for diabetes-associated ischaemic heart disease. Eur J Endocrinol 165:261–267
PubMed CrossRef Google Scholar 18.
Chen K, Wang YT, Gu W et al (2010) Functional significance of the Toll-like receptor 4 promoter gene polymorphisms in the Chinese Han population. Crit Care Med 38:1292–1299
PubMed CrossRef Google Scholar 19.
Sato K, Yoshimura A, Kaneko T (2012) A single nucleotide polymorphism in 3′-untranslated region contributes to the regulation of toll-like receptor 4 translation. J Biol Chem 287:25163–25172
PubMed CrossRef Google Scholar 20.
Hishida A, Matsuo K, Goto Y et al (2009) Toll-like receptor 4 +3725G/C polymorphism, Helicobacter pylori seropositivity, and the risk of gastric atrophy and gastric cancer in Japanese. Helicobacter 14:47–53
PubMed CrossRef Google Scholar 21.
Zhou L, Wei B, Xing C et al (2011) Polymorphism in 3′-untranslated region of toll-like receptor 4 gene is associated with protection from hepatitis B virus recurrence after liver transplantation. Transpl Infect Dis 13:250–258
PubMed CrossRef Google Scholar © Arányi Lajos Foundation 2012
Authors and Affiliations 1. Department of Urology General Hospital of Jinan Military Command Jinan People’s Republic of China